Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Conditions
Brief summary
This observational disease registry is a prospective, national, non-interventional study designed to enroll participants who have received an initial diagnosis of unresectable, locally advanced (LA) or metastatic breast cancer (mBC), up to 6 months prior to registry enrolment. These participants will be prospectively followed for at least 5 years after study enrolment to evaluate their anti-cancer treatments. Data on participants' previous anti-cancer treatments for breast cancer will be collected retrospectively at study entry.
Interventions
OTHERNo intervention
No intervention was administered in this study.
Sponsors
Hoffmann-La Roche
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrolment, although they can have received anti-cancer treatment during that time
Exclusion criteria
There are no
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival (PFS) For Each Anti-Cancer Treatment Regimen | Up to approximately 8 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) | Up to approximately 8 years |
| Objective Response Rate (ORR) For Each Anti-Cancer Treatment Regimen | Up to approximately 8 years |
| Number and Percentage of Participants Receiving Each Unique Treatment Regimen Overall and as First-Line Therapy Versus Second-Line Therapy Versus Subsequent-Line Therapy | Up to approximately 8 years |
Outcome results
None listed